Deka Bank Deutsche Girozentrale Alnylam Pharmaceuticals, Inc. Transaction History

Deka Bank Deutsche Girozentrale

$53.9 Billion
Q3 2024

A detailed history of Deka Bank Deutsche Girozentrale transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 113,193 shares of ALNY stock, worth $28.6 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

113,193

Previous 113,463 0.24%

Holding current value

$28.6 Million

Previous $27.9 Million 10.7%

% of portfolio

0.06%

Previous 0.05%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	SELL	$233.81 - $287.01 $63,128 - $77,492	-270 Reduced 0.24%	113,193 $30.9 Million
Q2 2024 Aug 08, 2024	BUY	$143.31 - $247.0 $60,333 - $103,987	421 Added 0.37%	113,463 $27.9 Million
Q1 2024 Apr 24, 2024	SELL	$146.51 - $198.2 $3.64 Million - $4.92 Million	-24,843 Reduced 18.02%	113,042 $17.3 Million
Q4 2023 Jan 24, 2024	SELL	$151.41 - $196.57 $789,603 - $1.03 Million	-5,215 Reduced 3.64%	137,885 $26.8 Million
Q3 2023 Nov 13, 2023	SELL	$170.77 - $211.65 $2.96 Million - $3.67 Million	-17,349 Reduced 10.81%	143,100 $24.8 Million
Q2 2023 Jul 25, 2023	BUY	$185.01 - $212.05 $6.74 Million - $7.72 Million	36,404 Added 29.35%	160,449 $30.6 Million
Q1 2023 Apr 24, 2023	BUY	$182.66 - $235.53 $6.15 Million - $7.94 Million	33,692 Added 37.29%	124,045 $24 Million
Q4 2022 Feb 01, 2023	BUY	$185.53 - $241.31 $364,009 - $473,450	1,962 Added 2.22%	90,353 $21.3 Million
Q3 2022 Nov 02, 2022	BUY	$138.54 - $232.0 $2.61 Million - $4.36 Million	18,804 Added 27.02%	88,391 $18.4 Million
Q2 2022 Aug 03, 2022	BUY	$120.42 - $169.29 $1.5 Million - $2.1 Million	12,419 Added 21.72%	69,587 $9.99 Million
Q1 2022 Apr 28, 2022	BUY	$127.18 - $173.91 $113,063 - $154,605	889 Added 1.58%	57,168 $9.52 Million
Q4 2021 Feb 02, 2022	BUY	$159.56 - $209.29 $1.89 Million - $2.48 Million	11,843 Added 26.65%	56,279 $9.54 Million
Q3 2021 Oct 22, 2021	SELL	$169.75 - $207.73 $4.95 Million - $6.06 Million	-29,155 Reduced 39.62%	44,436 $7.9 Million
Q2 2021 Aug 05, 2021	SELL	$128.63 - $176.89 $13,377 - $18,396	-104 Reduced 0.14%	73,591 $12.1 Million
Q1 2021 Apr 28, 2021	BUY	$126.83 - $175.69 $259,621 - $359,637	2,047 Added 2.86%	73,695 $9.91 Million
Q4 2020 Mar 12, 2021	SELL	$122.97 - $147.0 $1.3 Million - $1.55 Million	-10,540 Reduced 12.82%	71,648 $9.32 Million
Q3 2020 Oct 29, 2020	BUY	$121.19 - $165.49 $9.02 Million - $12.3 Million	74,464 Added 964.06%	82,188 $12 Million
Q2 2020 Aug 04, 2020	BUY	$104.21 - $156.44 $175,593 - $263,601	1,685 Added 27.9%	7,724 $1.14 Million
Q1 2020 May 14, 2020	SELL	$93.12 - $133.99 $22,255 - $32,023	-239 Reduced 3.81%	6,039 $650,000
Q4 2019 Feb 04, 2020	SELL	$74.51 - $124.23 $3.9 Million - $6.5 Million	-52,301 Reduced 89.28%	6,278 $731,000
Q3 2019 Nov 14, 2019	SELL	$70.9 - $87.82 $3.64 Million - $4.51 Million	-51,300 Reduced 46.69%	58,579 $4.77 Million
Q2 2019 Aug 01, 2019	BUY	$65.86 - $92.79 $4.24 Million - $5.97 Million	64,339 Added 141.28%	109,879 $7.84 Million
Q1 2019 May 10, 2019	BUY	$72.76 - $93.45 $685,981 - $881,046	9,428 Added 26.11%	45,540 $5.61 Million
Q4 2018 Feb 12, 2019	SELL	$62.67 - $88.33 $590,852 - $832,775	-9,428 Reduced 20.7%	36,112 $2.53 Million
Q3 2018 Nov 09, 2018	SELL	$87.52 - $122.67 $664,101 - $930,819	-7,588 Reduced 14.28%	45,540 $0
Q2 2018 Aug 14, 2018	SELL	$88.31 - $107.8 $1.15 Million - $1.4 Million	-12,978 Reduced 19.63%	53,128 $5.24 Million
Q1 2018 May 03, 2018	BUY	$115.92 - $148.54 $724,036 - $927,780	6,246 Added 10.43%	66,106 $8.64 Million
Q3 2017 Nov 06, 2017	BUY	$72.53 - $118.27 $4.34 Million - $7.08 Million	59,860	59,860 $4.86 Million

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.

Account

Deka Bank Deutsche Girozentrale Alnylam Pharmaceuticals, Inc. Transaction History